Clinical Trial Update: E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating E7070 in combination with idarubicin and cytarabine for relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• CYTARABINE (CYTARABINE)
• E7070
• Idarubicin (idarubicin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2018-07-03